Second Quarter 2023 Earnings

BioMarin is a Best-In-Class Genetic Disease Company at an Inflection Point of Transformative Growth Solid, Profitable, "IRA-proof" & Growing Base Business Anchored by durable enzyme-based therapies producing nearly $2B of revenue and positive operating cash flows. Steady revenue growth across the portfolio High barriers to entry results in lower risk of competition and long-lived revenue streams New Large-market Launches Are Significant Near-Term Growth Drivers ■ VOXZOGO® is the first and only approved treatment for Achondroplasia - tracking to blockbuster status ROCTAVIAN™, approved in the U.S. and Europe, is a safe and efficacious one-time treatment alternative to chronic therapy for eligible adults with severe hemophilia A Profit margin expansion expected as new product revenue growth leverages world class infrastructure Best-In-Class Innovation Capabilities. ◉ ◉ ◉ ◉ Industry-leading R&D teams produced suite of eight internally-developed genetic-based commercial therapies. Fully-integrated and scaled biopharma capabilities: Discovery, Clinical, Regulatory and world-class Manufacturing Leveraging decades of genetic expertise in current age of rapid genetic disease discovery Exceptional development success rate applied to deep early-stage pipeline with most assets in Company history

View entire presentation